Following variable Phase III outcomes, investigators are searching for more informative biomarkers than PD-L1 expression in advanced urothelial carcinoma cases.
Two studies presented at ASCO's virtual annual meeting demonstrated the clinical utility of germline findings in guiding treatment decisions in cancer.
A pilot project showed that clinics using the InheRET tool were able to gather more complete family history information from patients, which is important for further cancer risk evaluation.
Using data from cancer registries, investigators saw apparent disparities in the surgical interventions and treatments used for breast cancer patients with inherited cancer risk.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
A study of more than 5,000 breast cancer patients found that multi-gene sequencing has rapidly replaced BRCA1/2-only tests, resulting in better pathogenic variant detection but also higher VUS rates.
